Angiex Completes $45 million Series B Financing to Advance Its TM4SF1 Antibody-Drug Conjugate toward Clinical Development

18 August 2021

CAMBRIDGE, MA. (August 18, 2021) – Angiex Inc. today announced that it has completed the second and final closing of a $45 million Series B preferred equity financing. The financing was led by Presight Capital and included participation from Peter Thiel and other investors.

The capital will enable Angiex to bring its lead drug, AGX101, to IND acceptance and to further develop its pipeline of Nuclear-Delivered Antibody-Drug Conjugates™ (ND-ADCs). ND-ADCs utilize a tumor cell and vascular endothelial cell antigen, TM4SF1, to reach multiple cell types in solid tumors with high tumor selectivity.

“Angiex is very pleased that Presight Capital has joined our investor syndicate,” said Paul Jaminet, Ph.D., Angiex’s founder and President. “With this capital, we expect to bring our lead drug into the clinic and to further advance our drug pipeline.”

“Angiex is developing a radically new approach to cancer therapy,” said Dr. Harold Dvorak, Angiex founder and Chief Medical Officer and Mallinckrodt Distinguished Professor of Pathology Emeritus at Harvard Medical School. “Angiex’s approach simultaneously targets both tumor cells and tumor vessels. This comprehensive approach offers potential for efficacy against the most dangerous solid tumors.”

About Angiex

Angiex Inc. is a privately held biotech startup whose mission is to exploit newly discovered biological transport mechanisms to make drugs with revolutionary power over cancer. Based in Cambridge, Mass., Angiex was founded by a scientific team of leading experts in angiogenesis, vascular biology, and oncology. The company is developing a novel portfolio of Nuclear-Delivered Antibody-Drug Conjugates™ (ND-ADCs) that release therapeutic payloads directly into the nucleus or cytosol, where the site of payload action is located. This direct delivery holds the promise of enhancing the efficacy and therapeutic margin of conventional ADCs. The lead product, AGX101, has advanced through pre-clinical development and is about to begin Phase 1 clinical trials. To learn more about Angiex...